Financing will also support indication expansion of ELA026 in hematologic cancers and advance second pipeline program, ELA822, into the clinic for diseases in immunology and inflammation (I&I)
Financing co-led by Nextech and EQT Life Sciences, with participation from additional new investors including Sanofi, HBM Healthcare Investments, and Mubadala Capital, alongside existing investors
SOUTH SAN FRANCISCO, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Electra Therapeutics, a clinical stage biotechnology company pioneering therapies against novel targets for diseases in immunology and cancer, today announced an oversubscribed $183 million Series C financing. The round was co-led by Nextech and EQT Life Sciences, with participation from new investors Sanofi, HBM Healthcare Investments, and Mubadala Capital, as well as existing investors OrbiMed, Redmile Group, New Leaf Venture Partners, Westlake BioPartners, Cormorant Asset Management, Blue Owl Capital, and RA Capital Management.
Proceeds from the financing will fund a global pivotal Phase 2/3 study of ELA026 in secondary hemophagocytic lymphohistiocytosis (sHLH), a hyperinflammatory disease with high mortality and a lack of treatment options. The pivotal study is enrolling patients at research sites across the U.S. and Europe and has initiated dosing. Beyond sHLH, Electra is also evaluating ELA026 in hematologic ...
